Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 27, 2025 after market close.
The company's management team will host a conference call and webcast at 5:00 p.m. ET to discuss financial results and provide a corporate update. Participants can pre-register through a dial-in link and are advised to join 15 minutes before the start time. A replay will be available on the company's website, with the webcast remaining accessible for 90 days following the live call.
Plus Therapeutics (PSTV), un'azienda farmaceutica in fase clinica focalizzata nello sviluppo di radioterapici mirati per i tumori del sistema nervoso centrale (SNC), ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 marzo 2025 dopo la chiusura del mercato.
Il team di gestione dell'azienda ospiterà una conferenza telefonica e un webcast alle 5:00 p.m. ET per discutere i risultati finanziari e fornire un aggiornamento aziendale. I partecipanti possono registrarsi in anticipo tramite un link di accesso telefonico e sono invitati a unirsi 15 minuti prima dell'orario di inizio. Una registrazione sarà disponibile sul sito web dell'azienda, con il webcast accessibile per 90 giorni dopo la chiamata dal vivo.
Plus Therapeutics (PSTV), una empresa farmacéutica en etapa clínica centrada en el desarrollo de radioterapéuticos dirigidos para los cánceres del sistema nervioso central (SNC), ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de marzo de 2025 después del cierre del mercado.
El equipo de gestión de la empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 5:00 p.m. ET para discutir los resultados financieros y proporcionar una actualización corporativa. Los participantes pueden preinscribirse a través de un enlace de acceso telefónico y se les aconseja unirse 15 minutos antes de la hora de inicio. Una repetición estará disponible en el sitio web de la empresa, y la transmisión permanecerá accesible durante 90 días después de la llamada en vivo.
플러스 테라퓨틱스 (PSTV), 중앙 신경계(CNS) 암을 위한 표적 방사선 치료제를 개발하는 임상 단계의 제약 회사가 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일 목요일 시장 종료 후로 예정하고 있습니다.
회사의 경영진은 오후 5:00 ET에 재무 결과를 논의하고 기업 업데이트를 제공하기 위한 전화 회의 및 웹캐스트를 주최할 것입니다. 참가자는 전화 접속 링크를 통해 사전 등록할 수 있으며, 시작 시간 15분 전에 참여할 것을 권장합니다. 생방송 후 90일 동안 웹캐스트에 계속 접근할 수 있으며, 회사 웹사이트에서 재생할 수 있습니다.
Plus Therapeutics (PSTV), une entreprise pharmaceutique en phase clinique axée sur le développement de radiothérapeutiques ciblés pour les cancers du système nerveux central (SNC), a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour jeudi 27 mars 2025 après la clôture des marchés.
L'équipe de direction de l'entreprise animera une conférence téléphonique et un webinaire à 17h00 ET pour discuter des résultats financiers et fournir une mise à jour de l'entreprise. Les participants peuvent s'inscrire à l'avance via un lien d'appel et sont invités à rejoindre 15 minutes avant l'heure de début. Un enregistrement sera disponible sur le site web de l'entreprise, le webinaire restant accessible pendant 90 jours après l'appel en direct.
Plus Therapeutics (PSTV), ein klinisch tätiges Pharmaunternehmen, das sich auf die Entwicklung von zielgerichteten Radiotherapeutika für Tumoren des zentralen Nervensystems (ZNS) konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Donnerstag, den 27. März 2025 nach Börsenschluss angesetzt.
Das Management-Team des Unternehmens wird um 17:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu erörtern und ein Unternehmensupdate zu geben. Teilnehmer können sich über einen Einwahllink im Voraus registrieren und werden gebeten, 15 Minuten vor Beginn der Veranstaltung beizutreten. Eine Wiederholung wird auf der Unternehmenswebsite verfügbar sein, und der Webcast bleibt 90 Tage nach dem Live-Anruf zugänglich.
- None.
- None.
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
Webcast and Conference Call
| Date/Time: | Thursday, March 27, 2025 @ 5:00 PM ET |
| Webcast: | https://edge.media-server.com/mmc/p/5r5hkcqq |
| Dial-in Link: | https://register-conf.media-server.com/register/BI74b28f5ee02c4c1c89a835bfb6bdc1c8 |
Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements under the heading Upcoming Events and Expected Milestones, and statements regarding the following: CLIA compliance certification of the Company’s Houston-based clinical laboratory; the potential promise of rhenium (186Re) obisbemeda; expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts;; development and utility of CNSide leptomeningeal metastases diagnostic test.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, including the ability of the Company to come into compliance with The Nasdaq Capital Market listing requirements; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Jules Abraham
Managing Director, Communications
CORE IR
Julesa@coreir.com
FAQ
When will Plus Therapeutics (PSTV) release its Q4 and full year 2024 earnings?
What time is Plus Therapeutics (PSTV) Q4 2024 earnings call?
How long will PSTV's Q4 2024 earnings webcast be available for replay?
What is Plus Therapeutics' (PSTV) main business focus?
